BMP7通过NRF2/HO-1通路抑制氧化应激和卫星胶质细胞活化从而缓解三叉神经痛

BMP7 alleviates trigeminal neuralgia by suppressing oxidative stress and activation of satellite glial cells via the NRF2/HO-1 pathway

作者信息Meiqin Li, Gaopeng Guan, Xin Li, Dingquan Zou, Wei Zhang, Kai Chen, Yanying Xiao, Yaping Wang, Meng Wang
PMID41534727
发布时间2026-05
DOI10.1016/j.bbi.2026.106277

实验完整度

包含临床样本检测(CSF氧化应激标志物)、动物模型(CCI-dION大鼠)及细胞实验(原代SGCs),并进行BMP7敲低/过表达的功能验证及NRF2/HO-1通路抑制实验,体内外证据相互印证。

主要模型

三叉神经痛大鼠模型(CCI-dION) 原代大鼠卫星胶质细胞(DRG来源)

重点核对

TN模型构建:CCI-dION手术,结扎神经约30%直径 病毒注射:AAV-shBMP7或AAV-BMP7注入TG,剂量1μL,术后21天检测 细胞处理:IL-1β(10 ng/mL)刺激24小时诱导SGC活化 通路抑制:ML385(10 μM)预处理6小时

摘要

Background: The trigeminal ganglion (TG) is a central hub for craniofacial injurious messaging, and its abnormal function is closely related to the pathogenesis of trigeminal neuralgia (TN). Bone morphogenetic protein 7 (BMP7), a pleiotropic cytokine with both neuroprotective and anti-inflammatory effects, has been shown to have therapeutic potential for neuropathic pain (NP) and neurodegenerative diseases. However, it remains to be elucidated whether BMP7 is involved in the pathological process of TN through the regulation of TG. Objective: This study aimed to investigate whether BMP7 alleviates TN by modulating oxidative stress and activation in satellite glial cells (SGCs) of the TG. Methods: A rat model of TN was established by chronic constriction injury of the distal infraorbital nerve (CCI-dION). Primary rat SGCs were activated with IL-1β to create an in vitro model. The role of BMP7 in regulating oxidative stress was assessed through in vivo knockdown and in vitro overexpression experiments. The NRF2 inhibitor ML385 was employed to validate the essential role of the NRF2/HO-1 pathway in BMP7-mediated SGC functional modulation. Results: Following successful CCI-dION model establishment, TN rats showed significantly reduced mechanical pain thresholds, aggravated cold allodynia, and increased spontaneous pain behaviors, accompanied by decreased BMP7 expression, enhanced SGC activation, and elevated ROS levels in TG. These pathological phenotypes were consistently reproduced in BMP7-knockdown rats. In IL-1β-stimulated SGCs, BMP7 silencing mimicked pathological changes, while BMP7 overexpression reversed IL-1β effects - a rescue blocked by ML385. Critically, in vivo BMP7 overexpression attenuated CCI-dION-induced pain, oxidative stress, and SGC activation. Conclusion: This study demonstrates that BMP7 alleviates TN by suppressing oxidative stress and activation of SGCs through activation of the NRF2/HO-1 pathway, highlighting its therapeutic potential for TN treatment.

实验结论

提炼研究问题、关键发现与证据,快速把握文章的核心贡献。

研究问题
BMP7是否通过调节TG中卫星胶质细胞的氧化应激和活化来缓解三叉神经痛?
核心机制
BMP7通过激活NRF2/HO-1信号通路,抑制氧化应激(降低ROS、4-HNE、MDA)和SGC活化(降低GFAP、IL-6、TNF-α),从而缓解疼痛。
主要证据
在CCI-dION大鼠模型中,TG中BMP7表达下调,SGC活化;BMP7敲低加剧氧化应激和SGC活化并诱导疼痛行为,过表达则逆转;ML385阻断BMP7的保护效应。
研究意义
靶向SGCs中的BMP7信号通路可能是治疗TN的潜在新策略,本研究为BMP7从基础研究到临床应用的转化提供了理论基础。

研究路径

按研究推进顺序梳理实验设计、验证步骤与关键观察。

1

检测临床样本氧化应激标志物

评估TN患者CSF中氧化应激水平及其与疼痛严重程度的关系。

收集TN患者和对照组CSF,检测4-HNE和MDA水平,并进行相关性分析。

2

建立CCI-dION大鼠模型并验证疼痛行为

模拟TN病理状态,并确认模型成功。

对大鼠施行CCI-dION手术,检测机械痛阈、自发痛和冷刺激反应。

3

检测TN大鼠TG中氧化应激和SGC活化

验证TN模型中TG的氧化应激水平升高和SGC活化。

通过DHE染色检测ROS,IF/IHC检测GFAP、IL-6、TNF-α。

4

体外细胞实验探究BMP7功能

明确BMP7对SGC氧化应激和活化的影响。

分离培养原代大鼠SGC,用IL-1β诱导活化,进行BMP7敲低或过表达,检测GFAP、ROS、炎症因子。

5

体内验证BMP7敲低对TG的影响

验证BMP7敲低是否诱导氧化应激和SGC活化并引发疼痛。

通过立体定位注射AAV-shBMP7到大鼠TG,检测疼痛行为、GFAP、ROS、炎症因子。

6

体外验证NRF2/HO-1通路介导BMP7作用

验证BMP7是否通过NRF2/HO-1通路发挥抗氧化和抑制SGC活化的作用。

在BMP7过表达细胞中给予NRF2抑制剂ML385,检测NRF2、HO-1、GFAP、ROS和炎症因子。

7

体内验证BMP7过表达的治疗效果

探讨BMP7过表达对TN大鼠疼痛行为、氧化应激和SGC活化的影响。

在TN模型大鼠TG注射AAV-BMP7,检测疼痛行为、GFAP、ROS、炎症因子。

研究方法

按研究目的归类文中使用的方法,便于定位所需技术。

产品清单

实验环节名称品牌货号
DMEM/F12培养基Gibco--
胎牛血清Procell--
青霉素-链霉素Procell--
NRG1-β1MilliporeSigma--
胰酶Gibco--
70 μm细胞筛网NEST--
白细胞介素-1βThermo Fisher Scientific--
ML385----
二甲基亚砜Beyotime--
脂质体3000Thermo Fisher Scientific--
P3000Thermo Fisher Scientific--
AG RNAex Pro试剂Accurate Biotechnology--
EvoM-MLV逆转录试剂盒Accurate Biotechnology--
SYBR Green预混液qPCR试剂盒Accurate Biotechnology--
CFX Connect实时荧光定量PCR仪BIO-RAD--
RIPA裂解液Beyotime BiotechnologyP0013B
磷酸酶抑制剂混合物BimakeB15001
微量BCA蛋白定量试剂盒Yamei BiotechnologyZJ101
PVDF膜MilliporeIPVH00010
无蛋白快速封闭液ServicebioG2052
抗BMP7抗体Bioss Antibodiesbs-2242R
抗GFAP抗体Bioworld TechnologyBS6460
抗NRF2抗体AbmartT55136
抗HO-1抗体AbmartTA5393
辣根过氧化物酶标记二抗ProteintechSA00001-2
增强化学发光底物MilliporeWBKLS0500
化学发光成像系统Clinx Science InstrumentsChemiScope 6300
二氢乙啶Beyotime BiotechnologyS0063
DCFH-DA荧光探针Beyotime BiotechnologyS0033S
DAPIServicebioG1407
Hoechst 33342ServicebioG1011
IL-6 ELISA试剂盒Jiangsu Jingmei Biological Technology--
TNF-α ELISA试剂盒Jiangsu Jingmei Biological Technology--
4-HNE检测试剂盒Shanghai Jianglai BiotechnologyJL46304
MDA检测试剂盒Shanghai Jianglai BiotechnologyJL53632
柠檬酸盐缓冲液Servicebio--
Triton X-100MP Biomedicals194854
山羊血清SolarbioSL038
抗GFAP抗体(小鼠)Cell Signaling Technology3670
FITC标记山羊抗小鼠二抗ServicebioGB22301
Cy3标记山羊抗兔二抗ServicebioGB21303
抗IL-6抗体AiFang BiologicalAFRP0016
抗TNF-α抗体AiFang BiologicalAFRP0037
辣根过氧化物酶标记二抗(IHC)AiFang BiologicalAFIHC003
DAB显色底物SolarbioDA1010
中性树脂Sigma-AldrichH9627
伊文思蓝染料Solarbio--
AAV-BMP7Braincase Company--
AAV-shBMP7Hanbio Biotechnology--

关键环节

汇总复现实验时建议重点确认的条件及原文阅读提示。

环节核对要点
临床样本采集
CSF采集部位(TN: Meckel's cave;对照:腰椎蛛网膜下腔)、样本量(TN: n=30;对照:n=28)、排除标准符合性
阅读提示:Methods 2.1 Clinical data collection
动物模型建立
CCI-dION手术细节(神经结扎位置、结扎线间隔、结扎程度约30%)、动物品系、性别、年龄、体重
阅读提示:Methods 2.3 Chronic constriction injury of the distal infraorbital nerve (CCI-dION) rat model
病毒注射
AAV病毒类型(AAV9)、注射体积(1 μL)、注射坐标(bregma后4.5mm,旁开3.0mm,深度10.0mm)、病毒滴度(AAV-BMP7: 5.1×10^12 vg/mL;AAV-shBMP7: 1.4×10^12 vg/mL)
阅读提示:Methods 2.4 Stereotaxic viral injection
细胞培养与处理
SGCs来源(新生SD大鼠DRG)、培养条件(DMEM/F12+10%FBS+青霉素/链霉素+NRG1-β1)、IL-1β浓度(10 ng/mL)和处理时间(24h)、ML385浓度(10 μM)和预处理时间(6h)
阅读提示:Methods 2.8 Isolation and culture of primary rat SGCs; 2.9 Cell treatments
分子检测
Western blot抗体稀释比例(BMP7: 1:1000; GFAP: 1:5000; NRF2: 1:1000; HO-1: 1:1000)、qPCR引物序列、内参基因(GAPDH)
阅读提示:Methods 2.15 Western blotting; 2.14 RNA extraction and RT-qPCR